Catherine Wood's REGN Position Overview
Catherine Wood (via Ark Investment Management LLC) currently holds 12,142 shares of Regeneron Pharmaceuticals, Inc. (REGN) worth $6.83 M, representing 0.04% of the portfolio. First purchased in 2016-Q4, this long-term strategic position has been held for 36 quarters.
Based on 13F filings, Catherine Wood has maintained a strategic position in REGN, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2021, adding 767,152 shares. Largest reduction occurred in Q2 2021, reducing 505,922 shares.
Analysis based on 13F filings available since 2013 Q2
Catherine Wood's Regeneron Pharmaceuticals (REGN) Holding Value Over Time
Track share changes against reported price movement
Quarterly Regeneron Pharmaceuticals (REGN) Trades by Catherine Wood
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2016 | +623 | Add 0.00% | 622 | $366.56 |
| Q1 2017 | +68 | Add 10.93% | 690 | $386.96 |
| Q2 2017 | +544 | Add 78.84% | 1,234 | $491.09 |
| Q4 2017 | +2,762 | Add 0.00% | 2,761 | $375.95 |
| Q1 2018 | +564 | Add 20.43% | 3,325 | $344.36 |
| Q2 2018 | +15,257 | Add 458.86% | 18,582 | $345.01 |
| Q3 2018 | +4,658 | Add 25.07% | 23,240 | $404.04 |
| Q4 2018 | -9,319 | Reduce 40.10% | 13,921 | $373.46 |
| Q1 2019 | -684 | Reduce 4.91% | 13,237 | $410.59 |
| Q2 2019 | +15,356 | Add 116.01% | 28,593 | $313.01 |
| Q3 2019 | +11,480 | Add 40.15% | 40,073 | $277.39 |
| Q4 2019 | -39,984 | Reduce 99.78% | 89 | $370.79 |
| Q2 2020 | -89 | Sold Out | 89 | $0.00 |
| Q4 2020 | +451,818 | New Buy | 451,818 | $483.11 |
| Q1 2021 | +767,152 | Add 169.79% | 1.22 M | $473.14 |
| Q2 2021 | -505,922 | Reduce 41.50% | 713,048 | $558.54 |
| Q3 2021 | -284,901 | Reduce 39.96% | 428,147 | $605.18 |
| Q4 2021 | -355,154 | Reduce 82.95% | 72,993 | $631.53 |
| Q1 2022 | -15,220 | Reduce 20.85% | 57,773 | $698.42 |
| Q2 2022 | -1,962 | Reduce 3.40% | 55,811 | $664.74 |
| Q3 2022 | -18,870 | Reduce 33.81% | 36,941 | $688.88 |
| Q4 2022 | -2,888 | Reduce 7.82% | 34,053 | $721.49 |
| Q1 2023 | -462 | Reduce 1.36% | 33,591 | $821.67 |
| Q2 2023 | -1,338 | Reduce 3.98% | 32,253 | $718.54 |
| Q3 2023 | -4,513 | Reduce 13.99% | 27,740 | $822.96 |
| Q4 2023 | -9 | Reduce 0.03% | 27,731 | $878.28 |
| Q1 2024 | -9,518 | Reduce 34.32% | 18,213 | $962.50 |
| Q2 2024 | -2,348 | Reduce 12.89% | 15,865 | $1051.02 |
| Q3 2024 | -714 | Reduce 4.50% | 15,151 | $1051.27 |
| Q4 2024 | -1,959 | Reduce 12.93% | 13,192 | $712.35 |
| Q1 2025 | +502 | Add 3.81% | 13,694 | $634.22 |
| Q2 2025 | -1,088 | Reduce 7.95% | 12,606 | $525.00 |
| Q3 2025 | -464 | Reduce 3.68% | 12,142 | $562.29 |
Catherine Wood's Regeneron Pharmaceuticals Investment FAQs
Catherine Wood first purchased Regeneron Pharmaceuticals, Inc. (REGN) in Q4 2016, acquiring 622 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Catherine Wood has held Regeneron Pharmaceuticals, Inc. (REGN) for 36 quarters since Q4 2016. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Catherine Wood's largest addition to Regeneron Pharmaceuticals, Inc. (REGN) was in Q1 2021, adding 1,218,970 shares worth $576.74 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Catherine Wood's firm, Ark Investment Management LLC, owns 12,142 shares of Regeneron Pharmaceuticals, Inc. (REGN), valued at approximately $6.83 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Regeneron Pharmaceuticals, Inc. (REGN) represents approximately 0.04% of Catherine Wood's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Catherine Wood's peak holding in Regeneron Pharmaceuticals, Inc. (REGN) was 1,218,970 shares, as reported at the end of Q1 2021. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.